Abstract
We report a case of a 47-year-old female known with metastatic papillary thyroid cancer. Her treatment history included total thyroidectomy and 3 previous radio ablations with a cumulative dose of 950 mCi of 131I. On follow-up, her thyroglobulin levels had demonstrated a rising trend (from 3789.0 to 4240.0 ug/L) despite a 123I whole-body scan demonstrating a reduction in tracer avid lesions. She was suspected of having radio-resistant disease. The patient underwent both 18F-FDG and 68Ga-PSMA PET/CT imaging with both scans demonstrating congruent lesions however with far greater intensity on the 68Ga-PSMA study.
Keywords: 68Ga-PSMA, 18F-FDG, Thyroid cancer, Radioactive iodine refractory thyroid
Table 1.
Comparison of 18F-FDG and 68Ga-PSMA SUVR of reference lesions
| Lesion | Thyroid primary | Lung lesions | Lytic T10 lesion | Right femur lesion | Left first rib |
|---|---|---|---|---|---|
| 18F-FDG SUVR | 19.01 | 21.15 | 20.17 | 12.27 | 5.07 |
| 68Ga-PSMA SUVR | 75.51 | 21.34 | 139.55 | 137.98 | 31.24 |
Fig. 1.
A 47-year-old female with papillary thyroid cancer with metastases to the lungs, spine, and right proximal femur as demonstrated on her baseline 123I whole-body anterior and posterior images (a). Her treatment history included a total thyroidectomy in 2015, decompression and fusion T8–L2 in 2015, and 3 previous radio ablations with a cumulative dose of 950 mCi 131I. On follow-up, she presented with rising thyroglobulin levels, from 3789.0 to 4240.0 ug/L. 123I whole-body anterior and posterior images (b) demonstrated minimal 123I avid disease in keeping with radioactive iodine (RAI)–refractory disease [1]. Whilst patients with differentiated thyroid cancer can expect to have a good prognosis, those with RAI-refractory disease have poorer outcomes and succumb to their condition early [2].
Fig. 2.
18F-FDG PET/CT MIP (a) and fused axial soft tissue and lung window images (b, c) demonstrate residual thyroid tissue and lung metastases. Axial (d, e) 18F-FDG PET/CT fused bone window images demonstrated thoracic spinal and right femur metastatic lesions. The related standard uptake value ratio (SUVR) readings of lesions demonstrated in this figure are presented in Table 1. 18F-FDG PET/CT remains the recommended imaging modality in RAI-refractory disease, with an increasing sensitivity with rising thyroglobulin levels [3, 4]. Compared with the 123I whole-body scans (Fig. 1) the PET/CT images demonstrated a flip-flop phenomenon [5]. 68Ga-PSMA PET/CT, done 9 days after 18F-FDG PET/CT, MIP (f) and fused axial soft tissue and lung window (g, h) and axial skeletal window (i, j) demonstrated 68Ga-PSMA avid thyroid residual tissue, lung, and skeletal metastases. 68Ga-PSMA PET/CT images demonstrated far greater intense tracer uptake in the soft tissue and skeletal lesions compared with the 18F-FDG PET/CT scan; this was also confirmed by respective SUVR reference value comparison as noted in Table 1. Due to the fact that the injected activity for 18F-FDG is weight based whilst that for 68Ga-PSMA is fixed, SUVR rather than SUV max was the preferred semiquantitative method to compare lesion uptake between the two scans. The SUVR was calculated as a lesion to quadriceps muscle ratio using SUV mean. PSMA is a type II membrane antigen that is not only overexpressed in prostate cancer cells but has been demonstrated in other malignancies including thyroid and breast cancer as it overexpressed in tumor-associated neovasculature [6–8]. Tyrosine kinase inhibitors have taken a leading role in the management of patients with RAI-refractory thyroid cancer but suffer from side effects [9, 10]. To date, targeted radioligand therapy with 177Lu-PSMA has demonstrated good outcomes with limited side effects in the management of patients with metastatic castrate–resistant prostate cancer [11]. High uptake of the PSMA ligand on imaging is part of the requirements for consideration for treatment with 177Lu-PSMA radioligand therapy. To date, however, there is still limited evidence on the internalization and retention of therapeutic PSMA-labelled radioligands in de-differentiated thyroid cancer which is essential in the successful application of this radioligand treatment option for these patients. Imaging with 68Ga-PSMA in our case not only demonstrated the lesions visualized on 18F-FDG PET/CT but did so with a greater intensity suggesting possible suitability for theranostics with 177Lu-PSMA. 68Ga-PSMA PET/CT imaging in patients with RAI-refractory disease may prove to be a one-stop shop and should be considered as part of workup in these patients (Figure 2).
Acknowledgments
We would like to thank the staff of the Department of Nuclear Medicine of Steve Biko Academic Hospital for performing the scans.
Funding Information
This study was self-funded by the Department of Nuclear Medicine.
Compliance with Ethical Standards
Conflict of Interest
Thabo Lengana, Ismaheel O. Lawal, Kgomotso Mokoala, Mariza Vorster, and Mike M. Sathekge declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Footnotes
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. doi: 10.1089/thy.2015.0020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Pfister DG, Fagin JA. Refractory thyroid cancer: a paradigm shift in treatment is not far off. J Clin Oncol. 2008;26:4701–4704. doi: 10.1200/JCO.2008.17.3682. [DOI] [PubMed] [Google Scholar]
- 3.Silberstein EB. The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome. Semin Nucl Med. 2011;41:113–120. doi: 10.1053/j.semnuclmed.2010.10.002. [DOI] [PubMed] [Google Scholar]
- 4.Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med. 2012;37:953–959. doi: 10.1097/RLU.0b013e31825b2057. [DOI] [PubMed] [Google Scholar]
- 5.Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med. 1996;37:1468–1472. [PubMed] [Google Scholar]
- 6.Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192–3198. [PubMed] [Google Scholar]
- 7.Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, et al. (68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44:689–694. doi: 10.1007/s00259-016-3563-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bychkov A, Vutrapongwatana U, Tepmongkol S, Keelawat S. PSMA expression by microvasculature of thyroid tumors - potential implications for PSMA theranostics. Sci Rep. 2017;7:5202. doi: 10.1038/s41598-017-05481-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384:319–328. doi: 10.1016/S0140-6736(14)60421-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Paeng JC, Kang KW, Park DJ, Oh SW, Chung JK. Alternative medical treatment for radioiodine-refractory thyroid cancers. Nucl Med Mol Imaging. 2011;45:241–247. doi: 10.1007/s13139-011-0107-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kim YJ, Kim YI. Therapeutic responses and survival effects of 177Lu-PSMA-617 radioligand therapy in metastatic castrate-resistant prostate cancer: a meta-analysis. Clin Nucl Med. 2018;43:728–734. doi: 10.1097/RLU.0000000000001974. [DOI] [PubMed] [Google Scholar]